GE and Bracco spar over court ruling

April 2, 2009 Diagnostic Imaging. GE and Bracco spar over court ruling By Greg Freiherr The debate between GE and Bracco over GE's marketing of its Visipaque contrast agent continues despite a U.S. District Court finding that GE used false advertising to win sales for the x-ray contrast agent. GE Healthcare is permanently enjoined from making such claims and must pay Bracco damages of $11.4 million. The ruling is a consequence of litigation begun six years ago by Bracco and settled in a New Jersey court last week. In the days after the decision, however, executives at the two companies gave markedly different interpretations of the significance of the case and the court's findings. "The court found that there were some specific extrapolations that led to false advertising," said Eric Cantor, head of medical and professional affairs for GE Medical Diagnostics. "But the court in many ways found that the majority of GE Healthcare's messages were in fact true and were properly relied upon and were based on reliable scientific studies to support them."

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC